ClinicalTrials.gg

Bukwang Pharmaceutical clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 36 studies whose lead sponsor is Bukwang Pharmaceutical or one of 2 companies grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 16, 2026.

Our grouping of 3 registry names, not the registry’s. See them and correct one ↓

Compare Bukwang Pharmaceutical with Johnson & Johnson and CSPC Pharmaceutical Group →

Pipeline: 1 program

Each counted once: 1 with a study Bukwang Pharmaceutical leads registered in the last two years.

  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Bukwang Pharmaceutical’s own registered studies; Bukwang Pharmaceutical’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Bukwang Pharmaceutical’s studies test, most open studies first — 7 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

1 of Bukwang Pharmaceutical’s studies under way reach primary completion within a year, all of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. J
  9. J
  10. A
  11. S
  12. 1O
  13. N

Add it to your calendar (.ics) → With an account.

All 36 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now13%
  • Completed2467%
  • Stopped early1131%

Phase

  • Phase 411
  • Phase 39
  • Phase 29
  • Phase 15

Where

  • Korea, Republic of31
  • Italy2
  • Spain2
  • Germany1
  • South Africa1
  • United States1

Over the years

  1. 07
  2. 08
  3. 509
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 126

By the year each study started; 8 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Bukwang Pharmaceutical.

  • Bukwang Pharmaceutical
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    34 studies
  • Contera Pharma A/S
    Acquired — became part of Bukwang Pharmaceutical, Nov 24, 2014 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Contera Pharma
    Acquired — became part of Bukwang Pharmaceutical, Nov 24, 2014 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Studies

Recruiting first, then most recently updated. Showing 36 of 36.